Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1279-1287

  Camgoz, Aylin ^a   Gencer, Emel Basak ^a   Ural, Ali Ugur ^b   Baran, Yusuf ^a  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^b BAYINDIR HOSPITAL   (Turkey)

Author keywords

Chronic myeloid leukemia; Multidrug resistance; Nilotinib; Reversal of resistance

Indexed keywords

CASPASE 3; CERAMIDE; NILOTINIB;

ARTICLE; BAX GENE; BCR ABL GENE; CANCER CELL; CANCER RESISTANCE; CERS1 GENE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIDRUG RESISTANCE PROTEIN 1 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SK 1 GENE; TUMOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CASPASE 3; CELL LINE, TUMOR; CERAMIDES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84877748707     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.737919     Document Type: Article

References (37)

1. Druker BJ, O ' Brien SG, Cortes J, et al . Chronic myelogenous leukemia . Hematology Am Soc Hematol Educ Program 2002 : 111 - 135.
2. Koca E, Haznedaroglu IC . Imatinib mesylate and the management of chronic myeloid leukemia (CML) . Turk J Hematol 2005; 2 : 161 - 172.
3. Savage DG, Antman KH . Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002; 346: 683- 693.
4. Bonhoure E, Lauret A, Barnes DJ, et al . Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells . Leukemia 2008; 22: 971- 979.
5. Kantarjian H, G iles F, W underle L, et a l. N ilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354 : 2542 - 2551.
6. Talpaz M, Shah NP, Kantarjian H, et al . Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias . N Engl J Med 2006; 354 : 2531 - 2541.
7. Weisberg E, Manley PW, Breitenstein W, et al . Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl . Cancer Cell 2005; 7 : 129 - 141.
8. O ' Hare T, Walters DK, Deininger MW, et al . AMN107: Tightening the grip of imatinib . Cancer Cell 2005; 7 : 117 - 119.
9. Hughes T, Saglio G, Branford S, et al . Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase . J Clin Oncol 2009; 27 : 4204 - 4210.
10. Saglio G, Kim DW, Issaragrisil S, et al . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia . N Engl J Med 2010; 362 : 2251 - 2259.
11. Hochhaus A, Kreil S, Corbin AS, et al . Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy . Leukemia 2002; 16 : 2190 - 2196.
12. Ceylan C, Camgoz A, Baran Y . Macromolecular changes in nilotinib resistant K562 cells; an in vitro study by Fourier transform infrared spectroscopy . Technol Cancer Res Treat 2012; 11 : 333 - 344.
13. Hehlmann R, Berger U, Pfi rrmann M, et al . Drug treatment is superior to allografting as fi rst-line therapy in chronic myeloid leukemia . Blood 2007; 109 : 4686 - 4692.
14. Walz C, Sattler M . Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML) . Crit Rev Oncol Hematol 2006; 57 : 145 - 164.
15. D eininger M. R esistance to imatinib: Mechanisms and management . J Natl Compr Canc Netw 2005; 3: 757- 768.
16. Mahon FX, Deininger MW, Schultheis B, et al . Selection and characterization of BCR-ABL positive cell lines with diff erential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance . Blood 2000; 96 : 1070 - 1079.
17. Baran Y, Ural AU, Gunduz U . Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells . Hematology 2007; 12 : 497 - 503.
18. Mahon FX, Hayette S, Lagarde V, et al . Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008; 68: 9809- 9816.
19. Weisberg E, Griffi n J D. M echanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines . Blood 2000; 95 : 3498 - 3505.
20. Wang Y, Cai D, Brendel C, et al . Adaptive secretion of granulocytemacrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL - progenitors via JAK-2/STAT-5 pathway activation. Blood 2007; 109: 2147- 2155.
21. Reed JC . Bcl-2-family proteins and hematologic malignancies: History and future prospects . Blood 2008; 111 : 3322 - 3330.
22. Dai Y, Rahmani M, Corey SJ, et al . A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 . J Biol Chem 2004; 279 : 34227 - 34239.
23. Z amzami N, B renner C, M arzo I, et a l. S ubcellular and submitochondrial mode of action of Bcl-2-like oncoproteins . Oncogene 1998; 16 : 2265 - 2282.
24. Th omas D A, F aderl S, C ortes J, et a l. T reatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate . Blood 2004; 103 : 4396 - 4407.
25. J iang X, Z hao Y, S mith C, et a l. C hronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies . Leukemia 2007; 21: 926- 935.
26. Dohse M, Scharenberg C, Shukla S, et al . Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib . Drug Metab Dispos 2010; 38 : 1371 - 1380.
27. Brendel C, Scharenberg C, Dohse M, et al . Imatinib mesylate and nilotinib (AMN107) exhibit high-affi nity interaction with ABCG2 on primitive hematopoietic stem cells . Leukemia 2007; 21: 1267- 1275.
28. Hegedus C, Truta-Feles K, Antalff y G, et al . Interaction of the EGFR inhibitors gefi tinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance . Biochem Pharmacol 2012; 84 : 260 - 267.
29. Shen T, Kuang YH, Ashby CR, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the effl ux activity of the MRP7 (ABCC10). PLoS One 2009 ; 4 : E7520(1-9)
30. Ogretmen B, Hannun YA . Biologically active sphingolipids in cancer pathogenesis and treatment . Nat Rev Cancer 2004; 4 : 604 - 616.
31. Sobue S, Iwasaki T, Sugisaki C, et al . Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes . Leukemia 2006; 20 : 2042 - 2046.
32. F rench K J, S chrecengost R S, L ee B D, et a l. D iscovery and evaluation of inhibitors of human sphingosine kinase . Cancer Res 2003; 63 : 5962 - 5969.
33. Li QF, Wu CT, Guo Q, et al . Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis . Biochem Biophys Res Commun 2008; 371: 159- 162.
34. Baran Y, Salas A, Senkal CE, et al . Alterations of ceramide/ sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells . J Biol Chem 2007; 282 : 10922 - 10934.
35. B aran Y, B ielawski J, G unduz U, et a l. T argeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation . J Cancer Res Clin Oncol 2011; 137 : 1535 - 1544.
36. L iu Y Y, Han T Y, G iuliano A E, et a l. E xpression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells . J Biol Chem 1999; 274 : 1140 - 1146.
37. Venkataraman K, Futerman AH . Do longevity assurance genes containing Hox domains regulate cell development via ceramide synthesis? FEBS Lett 2002; 528 : 3 - 4.